Xenetic Biosciences, Inc.
XBIO
$3.02
-$0.12-3.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 766.30K | 1.03M | 589.90K | 593.30K | 648.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 766.30K | 1.03M | 589.90K | 593.30K | 648.80K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 766.30K | 1.03M | 589.90K | 593.30K | 648.80K |
| SG&A Expenses | 615.90K | 815.20K | 657.80K | 656.60K | 705.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.39M | 1.57M | 1.31M | 1.54M | 1.75M |
| Operating Income | -623.00K | -544.70K | -724.40K | -942.40K | -1.10M |
| Income Before Tax | -579.10K | -509.90K | -688.70K | -903.10K | -1.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -579.10K | -509.90K | -688.70K | -903.10K | -1.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -579.10K | -509.90K | -688.70K | -903.10K | -1.05M |
| EBIT | -623.00K | -544.70K | -724.40K | -942.40K | -1.10M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.27 | -0.33 | -0.45 | -0.59 | -0.68 |
| Normalized Basic EPS | -0.17 | -0.21 | -0.28 | -0.37 | -0.43 |
| EPS Diluted | -0.27 | -0.33 | -0.45 | -0.59 | -0.68 |
| Normalized Diluted EPS | -0.17 | -0.21 | -0.28 | -0.37 | -0.43 |
| Average Basic Shares Outstanding | 2.18M | 1.54M | 1.54M | 1.54M | 1.54M |
| Average Diluted Shares Outstanding | 2.18M | 1.54M | 1.54M | 1.54M | 1.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |